Compile Data Set for Download or QSAR
Report error Found 13 Enz. Inhib. hit(s) with all data for entry = 9898
TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM497357(diethyl (3-acetyl-1- (2-((2S,4R)-2-(2'- chloro-2- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2021
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM497370((3-acetyl-1-(2- ((2S,4R)-2-(2'- chloro-2- fluorobi...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2021
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM497377((3-acetyl-1-(2- ((2S,4R)-2-(6- bromopyridin-2- ylc...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2021
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM497378((2S,4R)-1-(2-(3- acetyl-6-(2- (dimethylamino)-2- o...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2021
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM497379((2S,4R)-1-(2-(3- acetyl-6-(2- (benzyloxy)ethoxy)- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2021
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM497380((2S,4R)-1-(2-(3- acetyl-6-(2- (methoxymethoxy) eth...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2021
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM497381((2S,4R)-1-(2-(3- acetyl-6-(2- hydroxyethoxy)-5- (2...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2021
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM497382((2S,4R)-1-(2-(3- acetyl-6-(2- (dimethylamino) etho...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2021
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM497383(tert-butyl((5-(3- acetyl-1-(2- ((2S,4R)-2-((6- bro...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2021
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM472455(US10822352, Comp No. 732 | (2S,4R)-1-(2-(3- acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2021
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM497385(tert-butyl ((3- acetyl-1-(2- ((2S,4R)-2-((6- bromo...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2021
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM468665((2S,4R)-1-(2-(3- acetyl-5-(S- methylsulfonimidoyl)...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2021
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM468660(tert-butyl ((3'- ((2S,4R)-1-(2-(3- carbamoyl-1H- i...)
Affinity DataIC50: 5.50E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2021
Entry Details
Go to US Patent